Search Results
Your search for ,200 matches 1611 pages
Showing 101 - 150Addition of Bevacizumab to Pembrolizumab in Platinum-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma
In a Singaporean phase II trial reported in The Lancet Oncology, Chong et al found that the addition of bevacizumab to pembrolizumab improved objective response rate in patients with platinum-resistant recurrent or metastatic nasopharyngeal carcinoma. Study Details In the open-label trial, 48...
Perioperative Chemotherapy vs Preoperative Chemoradiotherapy in Resectable Locally Advanced Esophageal Carcinoma
In a German phase III trial (ESOPEC) reported in The New England Journal of Medicine, Hoeppner et al found that perioperative chemotherapy with fluorouracil/leucovorin/oxaliplatin/docetaxel (FLOT) improved overall survival vs preoperative chemoradiotherapy in patients undergoing surgery for locally ...
UICC‘s New World Cancer Day Campaign Calls for Fundamental Shift in Cancer Care Delivery
The Union for International Cancer Control (UICC) has introduced the new 2025 to 2027 United by Unique campaign, calling for a fundamental shift in cancer care and health systems across the world toward a people-centered approach in light of World Cancer Day. World Cancer Day takes place on...
Advanced NSCLC With Brain Metastases: Potential Novel Therapeutic Option
In a Chinese phase II study (C-Brain) reported in The Lancet Oncology, Xu et al found that brain radiotherapy in combination with camrelizumab and platinum-doublet chemotherapy produced “promising” results in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with brain...
Does a New Blood-Based Screening Test Accurately Detect Colorectal Cancer Risk?
Colorectal cancer is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease. Although screening for the cancer through colonoscopy or sigmoidoscopy is effective in detecting the disease, nearly...
Intermittent or Continuous Panitumumab Plus FOLFIRI in First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer
In an Italian phase II trial (IMPROVE) reported in the Journal of Clinical Oncology, Avallone et al found that intermittent panitumumab and FOLFIRI (fluorouracil, leucovorin, and irinotecan) was associated with promising progression-free survival as first-line treatment in patients with RAS/BRAF...
Understanding the Assessment and Treatment of High-Risk Myelofibrosis
At the 2024 JADPRO Live event, which is held annually for advanced practitioners in oncology, high-risk myelofibrosis was a featured topic. “The treatment landscape has developed so much that JADPRO asked us to present our talks on the main stage this year,” said Julie Huynh-Lu, PA-C, Supervisor...
Novel Combination Studied in HPV16-Positive Relapsed or Metastatic Head and Neck Squamous Cell Carcinoma
Alan Ho, MD, PhD, recently presented updated results from a phase II trial evaluating the combination of an HPV16-targeted investigational immunotherapeutic agent eseba-vec (previously known as HB-200) and the PD-1 inhibitor pembrolizumab as first-line therapy for human papillomavirus type 16...
Lenvatinib/Pembrolizumab vs Chemotherapy in Advanced Endometrial Cancer
As reported in Journal of Clinical Oncology by Marth et al, the phase III European Network of Gynaecological Oncological Trial-en9/LEAP-001 study showed no significant differences in progression-free or overall survival with first-line lenvatinib/pembrolizumab vs chemotherapy in patients with...
Novel Hypofractionated Proton-Beam Therapy for Older Patients With Newly Diagnosed Glioblastoma
In a phase II trial reported in The Lancet Oncology, Vora et al found that short-course hypofractionated proton-beam therapy guided by 3,4-dihydroxy-6-[F-18]fluoro-L-phenylalanine (F-18–DOPA) positron-emission tomography (PET) and contrast-enhanced MRI produced good outcomes in patients aged ≥ 65...
Novel p53-MDM2 Inhibitor Plus Ribociclib Demonstrates Anticancer Activity in Liposarcoma Subset
The p53-MDM2 inhibitor siremadlin given with the CDK4/6 inhibitor ribociclib showed activity in a subset of patients with well-differentiated/dedifferentiated liposarcomas enrolled in the biology-driven adaptive phase II MEGAMOST Ribociclib/HDM201 basket trial.1 MEGAMOST was designed to evaluate...
Addition of Pembrolizumab to Radiation Therapy and Surgery in Stage III Soft-Tissue Sarcoma of the Extremity
In a phase II trial (SU2C-SARC032) reported in The Lancet, Mowery et al found that the addition of perioperative pembrolizumab to preoperative radiation therapy and surgery improved disease-free survival in patients with stage III soft-tissue sarcoma of the extremity. Study Details In the...
Addition of Veliparib to Temozolomide in Newly Diagnosed MGMT-Methylated Glioblastoma
In a phase II/III trial reported in JAMA Oncology, Sarkaria et al found that the addition of veliparib to temozolomide did not improve overall survival in patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation. Study Details In the double-blind Alliance for Clinical Trials...
Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma
In a phase I study reported in The Lancet Oncology, Maruyama et al found that valemetostat—a novel dual inhibitor of EZH2 and EZH1—showed activity in patients with relapsed or refractory non-Hodgkin lymphoma. Study Details In the study, 90 patients from sites in Japan and the United States were...
Study Finds In Situ Vaccination Using Tumor Treating Fields Plus Immune Checkpoint Inhibitors Extended Survival in Patients With Glioblastoma
A small study investigating tumor treating fields—an antimitotic electric fields therapy—in combination with pembrolizumab and temozolomide for the treatment of patients with glioblastoma was found to be a promising strategy, especially in patients with substantial residual tumor, according to the...
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In a phase III study conducted in China, the bispecific antibody (targeting both PD-1 and the vascular endothelial growth factor [VEGF]) ivonescimab was compared with the PD-1 inhibitor pembrolizumab as first-line treatment of PD-L1–positive advanced non–small cell lung cancer (NSCLC). Ivonescimab ...
Unexpected Results in Solid Tumors: What We Learned From Negative Findings
Attendees at the European Society for Medical Oncology (ESMO) Congress 2024 heard the results of many positive clinical trials that will advance the field of cancer treatment. However, a few late-stage trials of promising adjuvant therapies unexpectedly reported negative results. The ASCO Post...
Evolving Role of MRD Status in Multiple Myeloma
The use of measurable (or minimal) residual disease (MRD) status to guide treatment in multiple myeloma has become a topic of intense interest. Phase III studies presented at the Plenary Session of the 2024 International Myeloma Society Annual Meeting moved MRD status ever closer to validation in...
Valemetostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
In a phase II trial (VALENTINE-PTCL01) reported in The Lancet Oncology, Zinzani et al found that valemetostat—a novel dual inhibitor of EZH1 and EZH2—was active in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). Study Details In the trial, 133 patients with relapsed or...
DKN-01 With Tislelizumab and Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
In a phase IIa study (DisTinGuish) reported in the Journal of Clinical Oncology, Klempner et al found that use of the DKK1-neutralizing antibody DKN-01 in combination with tislelizumab and chemotherapy showed activity in the first-line treatment of patients with advanced gastric or gastroesophageal ...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting. Background Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science,...
Preoperative Chemotherapy and Perioperative Nivolumab in NSCLC
As reported in The Lancet Oncology by Provencio et al, analysis of a Spanish phase II trial (NADIM) showed good long-term outcomes with preoperative chemotherapy and perioperative nivolumab in patients with stage IIIA non-small cell lung cancer (NSCLC). Study Details In the multicenter trial, 46...
Do Social Support Measures Improve Uptake of Cancer Screening?
Although improving cancer screening participation in the United States is central to the country’s national goals for reducing disability and death, currently, participation is lagging behind the Healthy People 2030 targets set by the U.S. Department of Health and Human Services. A study by the...
Sintilimab/Bevacizumab in Relapsed or Persistent Ovarian Clear Cell Carcinoma
In a Chinese phase II trial (INOVA) reported in The Lancet Oncology, Peng et al found that the combination of sintilimab and bevacizumab showed activity in patients with relapsed or persistent ovarian clear cell carcinoma. Study Details In the multicenter trial, 37 evaluable patients with exposure...
LuPSMA vs Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients With Metastatic Castration-Resistant Prostate Cancer
As reported in The Lancet by Morris et al, the phase III PSMAfore trial has shown improved progression-free survival with lutetium-177–labeled PSMA-617 (LuPSMA) vs change in androgen receptor pathway inhibitor (ARPI) in taxane-naive patients with metastatic castration-resistant prostate cancer...
KEYNOTE-671: Overall Survival With Perioperative Pembrolizumab in Resectable NSCLC
As reported in The Lancet by Spicer et al, overall survival results of the phase III KEYNOTE-671 trial indicate benefit of the addition of neoadjuvant pembrolizumab to chemotherapy followed by adjuvant pembrolizumab in patients with early-stage non–small cell lung cancer (NSCLC). At the first...
EMBER: Imlunestrant in Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer
In the the phase IA/B dose-escalation and -expansion EMBER study reported in the Journal of Clinical Oncology by Jhaveri et al, the next-generation oral selective estrogen receptor degrader imlunestrant (alone and in combination with other targeted therapies) demonstrated a manageable safety...
Overall Survival Results With Pembrolizumab and Chemoradiotherapy in Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer
As reported in The Lancet by Lorusso et al, overall survival results from the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial indicated a significant benefit of pembrolizumab vs placebo with concurrent chemoradiotherapy followed by pembrolizumab vs placebo in patients with newly diagnosed,...
KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy
In the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at the European Society for Medical Oncology (ESMO) Congress 2024, the PD-1 inhibitor pembrolizumab plus chemoradiotherapy, with pembrolizumab continued as monotherapy, improved overall survival in previously untreated, high-risk...
Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
On April 29, 2024, tisotumab vedotin-tftv (Tivdak) was granted regular approval for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.1 Tisotumab vedotin is a tissue factor–directed antibody and microtubule inhibitor conjugate. The agent was granted...
Impact of Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm–Derived Pancreatic Cancer
In a retrospective cohort study reported in the Journal of Clinical Oncology, Habib et al found that adjuvant chemotherapy benefited some groups of patients with resected intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC), but that overtreatment and...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 1
Medical oncology had a turbulent beginning. No other specialty we know of struggled as much. But by 1980, it had become a stable specialty of internal medicine and was off and running—with the major problem of how to marshal available resources to freely test the myriad opportunities presented by ...
FDA Approves Pembrolizumab With Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
On September 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma. Efficacy and Safety Efficacy was investigated in KEYNOTE-483...
HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC
In a phase III study conducted in China, the bispecific antibody ivonescimab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with the PD-1 inhibitor pembrolizumab as a first-line treatment of PD-L1–positive advanced non–small...
Addition of Pembrolizumab to Chemotherapy in EGFR TKI-Resistant, EGFR-Mutant, Metastatic Nonsquamous NSCLC
As reported in the Journal of Clinical Oncology by Yang et al, the phase III KEYNOTE-789 trial has shown no significant improvement in progression-free or overall survival with the addition of pembrolizumab to pemetrexed/platinum in EGFR tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant...
New Studies Explore Relationships Between Heart Failure and Lymphoma, Arterial Thromboembolism and Cancer
In two studies recently reported in JACC: CardioOncology, Upshaw and colleagues1 examined the impact of preexisting heart failure on mortality in older patients in the United States with newly diagnosed Hodgkin lymphoma, and Gon and colleagues2 analyzed the incidence and impact of arterial...
Adjuvant Pembrolizumab vs Placebo in Stage III Melanoma: Long-Term Health-Related Quality of Life
In an analysis from the phase III EORTC 1325-MG/KEYNOTE-054 trial reported in The Lancet Oncology, Bührer et al found that adjuvant pembrolizumab was not associated with significant differences in long-term health-related quality of life (HRQOL) compared with placebo in patients with stage III...
Can Neoadjuvant Atezolizumab Set a New Standard for Unresectable Stage III NSCLC?
Immune checkpoint inhibitors, including atezolizumab, have been evaluated in several phase II trials for neoadjuvant therapy in resectable lung cancer, both with and without chemotherapy, such as the LCMC3 trial and CheckMate 816. Ongoing studies, including the IMpower030 trial, are further...
EGFR- and ALK-Altered NSCLC: TKIs With Stereotactic Radiosurgery for Brain Metastases
In a retrospective study (TURBO-NSCLC) reported in the Journal of Clinical Oncology, Pike et al found that the addition of upfront stereotactic radiosurgery (SRS) to central nervous system (CNS)-penetrant tyrosine kinase inhibitor (TKI) treatment prolonged time to CNS progression vs TKI treatment...
Recurrent/Metastatic HNSCC: Pembrolizumab Plus Carboplatin and Paclitaxel
As reported in the Journal of Clinical Oncology by Marcin Dzienis, MD, and colleagues, the phase IV KEYNOTE-B10 trial of pembrolizumab plus carboplatin and paclitaxel in the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) showed that the regimen produced...
Guardant Health’s Shield Blood Test Approved by the FDA as a Primary Screening Option for Colorectal Cancer
On July 29, the U.S. Food and Drug Administration (FDA) approved Guardant Health’s Shield blood test for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for...
Neoadjuvant Camrelizumab Plus Apatinib in Locally Advanced Colorectal Cancer
In a Chinese phase II study (NEOCAP) reported in The Lancet Oncology, Yu et al found that neoadjuvant camrelizumab plus apatinib produced promising complete response rates in patients with locally advanced microsatellite instability–high or mismatch repair–deficient colorectal cancer. Study ...
Can Living in a Disadvantaged Area Increase the Risk of Aggressive Prostate Cancer?
Those living in disadvantaged neighborhoods have significantly higher activity of stress-related genes, new research suggests, which in turn may contribute to higher rates of aggressive prostate cancer in African American men. These findings were published by Boyle et al in JAMA Network Open....
Advanced Classical Hodgkin Lymphoma: PET-Guided BrECADD vs eBEACOPP
As reported in The Lancet by Peter Borchmann, MD, and colleagues, the phase III HD21 trial showed that first-line positron-emission tomography (PET)-guided BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) exhibited greater efficacy and...
Nasopharyngeal Carcinoma: Adding Sintilimab to Standard Chemoradiotherapy for Locoregionally Advanced Disease
Based on the results of the Chinese multicenter phase III CONTINUUM trial, which were reported in The Lancet by Liu et al, the addition of the PD-1 inhibitor sintilimab to standard chemoradiotherapy seemed to improve event-free survival—albeit with more frequent but manageable adverse events—in...
Relapsed or Refractory Multiple Myeloma: Activity of BCMA x CD3 Bispecific Antibody
As reported in the Journal of Clinical Oncology by Bumma et al, the phase II portion of a first-in-human phase I/II trial (LINKER-MM1) showed strong activity with the B-cell maturation antigen (BCMA) x CD3 bispecific antibody linvoseltamab in patients with relapsed or refractory multiple myeloma....
Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer
Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III...
Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP
As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...
Recurrent or Metastatic HNSCC: First-Line VEGFR2 Plus PD-1 Inhibition
In a single-center phase I/II trial reported in The Lancet Oncology, Douglas Adkins, MD, and colleagues found that the recommended phase II dose of ramucirumab combined with pembrolizumab was active in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell...
ER-Positive Advanced Breast Cancer: Oral SERD Plus Palbociclib in First-Line Setting
As reported in the Journal of Clinical Oncology by Javier Cortés, MD, PhD, and colleagues, the phase III AMEERA-5 trial of first-line treatment with the selective estrogen receptor degrader (SERD) amcenestrant plus palbociclib vs letrozole plus palbociclib in estrogen receptor (ER)-positive,...
